CoChat

FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study

Open access
on behalf of Alzheimer’s Disease Neuroimaging Initiative, Ou, Ya-Nan, Xu, Wei, Li, Jie-Qiong, Guo, Yu, Cui, Mei, Chen, Ke-Liang, Huang, Yu-Yuan, Dong, Qiang, Tan, Lan, Yu, Jin-Tai · 2019 · Alzheimer's Research & Therapy

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

BACKGROUND: F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer's disease (AD) biological definition. However, accumulating evidence suggested it is an independent biomarker, which is denoted as "F" in the very study. METHODS: A total of 551 A+T+ individuals from the Alzheimer's Disease Neuroimaging Initiative database were recruited and then further divided into four groups based on the biomarker positivity as 132 A+T+N-F-, 102 A+T+N-F+, 113 A+T+N+F-, and 204 A+T+N+F+. Frequency distributions of the groups were compared, as well as the clinical progression [measured by the longitudinal changes in cognition and brain structure, and mild cognitive impairment (MCI) to AD dementia conversion] between every pair of F+ and F- groups. RESULTS: The prevalence of A+T+N+F+ profile was 66.24% in clinically diagnosed AD dementia patients; similarly, the majority of individuals with reduced FDG-PET were AD dementia subjects. Among the 551 individuals that included, 537 had at least one follow-up (varied from 1 to 8 years). Individuals in F+ groups performed worse and dropped faster in Mini-Mental State Examination scale and had faster shrinking middle temporal lobe than those in F- groups (all p < 0.05). Moreover, in MCI patients, reduced FDG-PET exerted 2.47 to 4.08-fold risk of AD dementia progression compared with those without significantly impaired FDG-PET (both p < 0.001). CONCLUSIONS: Based on the analyses, separating FDG-PET from "N" biomarker to build the ATN(F) system is necessary and well-founded. The analysis from this study could be a complement to the original ATN framework for AD's biological definition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-019-0512-1

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Plots of ATN(F) group characteristics. Box plots of continuous variables and bar charts summarized percentages of categorical variables from Table 1. As illustrated in Table 1, the four groups are arranged left-right hierarchically on the basis of A+T+, then the differences between F− vs F+ on the basis of N− and N+ were demonstrated. Significant p values of comparisons of every pair of F+ vs F− subgroups were depicted at the top of each figure. Abbreviations: MMSE, Mini-Mental State Examination; RAVLT-total, Rey Auditory Verbal Learning Test-immediate-total
Fig. 1 Plots of ATN(F) group characteristics. Box plots of continuous variables and bar charts summarized percentages of categorical variables from Table 1. As illustrated in Table 1, the four groups are arranged left-right hierarchically on the basis of A+T+, then the differences between F− vs F+ on the basis of N− and N+ were demonstrated. Significant p values of comparisons of every pair of F+ vs F− subgroups were depicted at the top of each figure. Abbreviations: MMSE, Mini-Mental State Examination; RAVLT-total, Rey Auditory Verbal Learning Test-immediate-totalCC BY · PubMed Central
Fig. 2 Frequency distributions of cognitive diagnosis and ATN(F) profiles among different groups. a The distributions of the four ATN(F) profiles in the population with different cognitive states. b Among the four ATN(F) groups, the various distributions of four cognitive states. Abbreviations: CN, cognitively normal; sMCI, stable mild cognitive impairment; pMCI, progressive mild cognitive impairment; AD, Alzheimer’s disease
Fig. 2 Frequency distributions of cognitive diagnosis and ATN(F) profiles among different groups. a The distributions of the four ATN(F) profiles in the population with different cognitive states. b Among the four ATN(F) groups, the various distributions of four cognitive states. Abbreviations: CN, cognitively normal; sMCI, stable mild cognitive impairment; pMCI, progressive mild cognitive impairment; AD, Alzheimer’s diseaseCC BY · PubMed Central
Fig. 3 Clinical progression between every pair of F+ and F− groups. a, c, e The comparisons of longitudinal changes in cognitive performances and brain structure with A+T+N+F- vs A+T+N−F- revealed in a, A+T+N+F+ vs A+T+N+F- in c, and A+T+N-F+ vs A+T+N+F- in e. Differences between every pair of F+ and F− subgroups were demonstrated by estimates with 95% CIs and p values. Analyses of cognitive decline were adjusted for age, gender, APOE ε4, and years of education. Analyses of brain atrophy were adjusted for age, gender, APOE ε4, and total intracranial volume. b, d, f The Kaplan-Meier curves showing cumulative probability of MCI to AD dementia progression, which were arranged in accordance with the order mentioned above. The small crosses are censored data, and the number of subjects at risk is noted at the bottom of the plot. The unadjusted p values of log-rank test were depicted in the lower left. Abbreviations: MMSE, Mini-Mental State Examination; RAVLT-total, Rey Auditory Verbal Learning Test-immediate-total; MTL, middle temporal volume; EC, entorhinal cortex; MCI, mild cognitive impairment; AD Alzheimer’s disease
Fig. 3 Clinical progression between every pair of F+ and F− groups. a, c, e The comparisons of longitudinal changes in cognitive performances and brain structure with A+T+N+F- vs A+T+N−F- revealed in a, A+T+N+F+ vs A+T+N+F- in c, and A+T+N-F+ vs A+T+N+F- in e. Differences between every pair of F+ and F− subgroups were demonstrated by estimates with 95% CIs and p values. Analyses of cognitive decline were adjusted for age, gender, APOE ε4, and years of education. Analyses of brain atrophy were adjusted for age, gender, APOE ε4, and total intracranial volume. b, d, f The Kaplan-Meier curves showing cumulative probability of MCI to AD dementia progression, which were arranged in accordance with the order mentioned above. The small crosses are censored data, and the number of subjects at risk is noted at the bottom of the plot. The unadjusted p values of log-rank test were depicted in the lower left. Abbreviations: MMSE, Mini-Mental State Examination; RAVLT-total, Rey Auditory Verbal Learning Test-immediate-total; MTL, middle temporal volume; EC, entorhinal cortex; MCI, mild cognitive impairment; AD Alzheimer’s diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 166

Metadata

Authors
Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., & Yu, J.-T.
Affiliations
  • Qingdao University (CN)
  • Shanghai Medical College of Fudan University (CN)
Corresponding author
Yu, Jin-Tai
Venue
Alzheimer's Research & Therapy
Published
2019-06-29
Volume
11
Issue
1
Pages
57-57
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2953750178
Cited by
155
References
50
Citations by year
2026: 10 · 2025: 23 · 2024: 25 · 2023: 28 · 2022: 26 · 2021: 26 · 2020: 16 · 2019: 1
FWCI
13.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH-12, W81XWH1220012, AG024904)
  • Foundation for the National Institutes of Health (W81XWH-12-2-0012, U01AG024904, Grant U01 AG024904, AG024904)
  • Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012)
  • Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Pfizer (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • University of Southern California (W81XWH-12-2-0012, U01 AG024904)
  • F. Hoffmann-La Roche (W81XWH-12-2-0012, AG024904, U01 AG024904)
  • Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Alzheimer's Disease Neuroimaging Initiative (W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2-, Department of Defense award number W81XWH-12-2-0012)
  • BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
  • Novartis Pharmaceuticals Corporation (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012)
  • National Natural Science Foundation of China (81771148, 2018YFC1314700, 91849126, U01 AG024904, W81XWH-12-2-0012, 2018SHZDZX01, 81571245)
  • Fudan University (2018SHZDZX01)
  • Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • Servier (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • H. Lundbeck A/S (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • National Institutes of Health (3u01ag024904-10s2, W81XWH, W81XWH-12-2-0012, U01-AG024904, Grant U01 AG024904, AG024904)
  • Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904)
  • Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
  • National Institute on Aging (U01-AG-024904, W81XWH-12-2–0012, AG 024904)
  • National Institute of Biomedical Imaging and Bioengineering (W81XWH-12-2-0012, U01 AG024904, AG024904)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
FDG-PET, Alzheimer's disease, biological diagnosis, neurodegeneration biomarkers, brain glucose metabolism, mild cognitive impairment, conversion to dementia, cognitive decline, Alzheimer's Disease Neuroimaging Initiative
MeSH terms
Aged, Alzheimer Disease, Brain, Female, Humans, Longitudinal Studies, Male, Biomarkers, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. https://app.cochat.ai/papers/10.1186/s13195-019-0512-1
The paper
Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., & Yu, J.-T. (2019). FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-019-0512-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.